Reducing Bone Metastases in Hormone-Resistant Prostate Cancer If you have metastatic, hormone-resistant prostate cancer and are concerned about metastases to bone, the following short articles could be of interest to you and especially to your medical practitioner, with whom they should be shared. They are written for physicians and come from a website called Cancer Network – Oncology. Prostate cancer’s unique affinity for metastasis to the bone creates a unique need to prevent skeletal-related events (SREs) in order to maximize mobility and quality of life. These articles describe the use of bone supportive agents such as denosumab (Xgeva®) and zoledronic acid (Reclast®) as well as life-extending anticancer therapies such as enzalutamide (Xtandi®), abiraterone (Zytiga®) and radium-223 chloride (alpharadin or Xofigo®). The linked articles are as follows: a) “Reducing Skeletal-Related Events in Metastatic, Castration (Hormone) Resistant Prostate Cancer” ; b) “Hitting Prostate Cancer Where It Hurts: Maximizing Control of Osseous Metastases”; and, c) “Progress in Prostate Cancer – at Last”, an encouraging article that contrasts progress in breast cancer with prostate cancer. Remember to share these with your physician if they apply to your situation.